AIkido Pharma Inc. Stock: price and insider trades · United States · SEC (Form 4)

About AIkido Pharma Inc.

AIkido Pharma Inc. (ticker: AIKI) is a United States biotechnology company listed on the NASDAQ market. For French-speaking investors in France, Belgium, or Switzerland, it should be viewed as a small-cap, high-risk biotech story whose investment case has historically been tied to drug discovery and early-stage development rather than commercial sales. The company was originally formed in 1967, which gives it a long corporate history, although its strategic identity has changed substantially over time. Public filings and company materials indicate that since 2017 the business has operated as a biotechnology developer focused on small-molecule therapeutic programs, with emphasis on oncology and, at times, antiviral research. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) Scientifically, AIkido has described a pipeline built around patented technology licensed from universities and researchers, with collaborations referenced with the University of Texas at Austin, the University of Maryland Baltimore, and Wake Forest University. Its disclosed therapeutic focus has included pancreatic cancer, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and a broad-spectrum antiviral platform. The company has also referred to preclinical work in prostate and pancreatic cancer. These are important data points, but they should be interpreted as development-stage assets rather than validated commercial products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) From a competitive standpoint, AIkido is best understood as a pipeline-driven biotech rather than a diversified pharmaceutical company. That means its market position depends on the strength of preclinical or clinical proof-of-concept, intellectual property, licensing terms, and financing capacity. In practical terms, the equity behaves more like an R&D option on future clinical success than like a mature healthcare franchise with recurring product revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) Geographically, the company is based in the United States. Its website lists an address at One Rockefeller Plaza in New York, NY, while SEC filings identify the issuer as a Delaware corporation. Recent filings also reference R&D space in New York and an East Coast headquarters in Jersey City, New Jersey. For international investors, that means the name is firmly embedded in the U.S. regulatory environment and subject to NASDAQ disclosure standards and SEC reporting requirements. ([aikidopharma.com](https://www.aikidopharma.com/about?utm_source=openai)) Recent public news has been more centered on financing, corporate structure, and regulatory filings than on major commercial milestones. That makes Form 4 insider transaction monitoring particularly relevant, because insider activity can provide clues about management sentiment, capital structure pressure, or upcoming corporate catalysts. Overall, AIKI remains a speculative U.S. biotech security whose valuation is likely to be driven by clinical news flow, licensing progress, and balance-sheet developments rather than current operating earnings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390022010395/ea156372ex99-1_aiki.htm?utm_source=openai))